Therapy News and Research

RSS

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Alliance HealthCare Services receives Exceeding Patient Expectations Award for 2009

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, has been awarded the prestigious Exceeding Expectations Award for 2009 by Avatar International, an industry leader in healthcare quality improvement services. Alliance also earned the award in 2007 and 2008.

13 Aug 2010

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

The American Society of Hematology has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released today in Blood, ASH's premier scientific journal, in the article titled "Enhancing Research in Regenerative Medicine."

13 Aug 2010

Interbots to provide robot based therapy for autistic children

Interbots, Inc., a high-tech spin-off company associated with the Carnegie Mellon University Entertainment Technology Center has teamed up with the Autism Center of Pittsburgh to provide innovative robot-based therapy for children with autism.The program, "Character Therapy," through the use of the Interbot robot "Popchilla" will test the ability of children with autism with limited or no verbal skills.

13 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

$Study demonstrates efficacy of vertebroplasty in treatment of acute vertebral compression fractures$

Study demonstrates efficacy of vertebroplasty in treatment of acute vertebral compression fractures

Orthovita, Inc., an orthobiologics and biosurgery company, notes that the August 10, 2010 online edition of The Lancet includes the largest peer-reviewed study to date demonstrating the efficacy of vertebroplasty in the treatment of acute vertebral compression fractures compared to conservative treatment.

12 Aug 2010

Numerate collaborates with Intellikine to identify drug-like inhibitors of PI3 kinase alpha

Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine's unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate's powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.

12 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

BioGenerator, a non-profit, seed-stage economic development funding group, today announced that it has led a round of early-stage financing for Pulse Therapeutics, Inc., a St. Louis company headquartered at the Center for Emerging Technologies. Pulse Therapeutics develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT). Other investors who participated in the round were Missouri Technology Corporation (MTC), Washington University's Olin School of Business Skandalaris Student Venture Fund, and Integrated Magnetics, of Culver City, California. The funds will be used for further pre-clinical development.

12 Aug 2010

Somaxon second-quarter net loss reduces to $5.7 million

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.

12 Aug 2010

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

Seattle Genetics, Inc. announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group. Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.

12 Aug 2010

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

The NIH has granted a University of Texas at Dallas researcher and a university-affiliated biomedical firm $1.7 million to investigate whether nerve stimulation offers a long-term cure for tinnitus.

12 Aug 2010

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

AdvanDx today announced the launch of its CE-IVD marked GNR Traffic Light™ PNA FISH® test in Europe. GNR Traffic Light PNA FISH is the first-ever test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes.

12 Aug 2010

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today that a U.S. Food and Drug Administration advisory committee voted unanimously that clinical studies had provided substantial evidence of the effectiveness of ezogabine as adjunctive treatment for adults with partial-onset seizures.

12 Aug 2010

Study examines cosmetic impact of surgical procedure for body dysmorphic disorder

A new study finds that while many who suffer from body dysmorphic disorder (BDD) seek cosmetic procedures, only two percent of procedures actually reduced the severity of BDD. Despite this poor long-term outcome, physicians continue to provide requested surgeries to people suffering from BDD. The study was recently published in Annals of Plastic Surgery.

12 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

Syndax raises $6 million to support ENCORE 301 study in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that it has issued $6M in convertible notes and warrants to its Series A investors bringing the total investment to date to $55M. All current investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.

12 Aug 2010

Scientists find therapeutic potential of stem cells for acute lung injury

Researchers are reporting this week new study results they say provide further evidence of the therapeutic potential of stem cells derived from bone marrow for patients suffering from acute lung injury, one of the most common causes of respiratory failure in intensive care units.

12 Aug 2010

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Augmenix, Inc. announced today that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed a commercial implantation of the company's CE Mark approved SpaceOAR System. The SpaceOAR hydrogel (from spacing Organs At Risk) is designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues.

12 Aug 2010

Therapy News and Research

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Alliance HealthCare Services receives Exceeding Patient Expectations Award for 2009

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

Interbots to provide robot based therapy for autistic children

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Study demonstrates efficacy of vertebroplasty in treatment of acute vertebral compression fractures

Numerate collaborates with Intellikine to identify drug-like inhibitors of PI3 kinase alpha

Tengion announces clinical, corporate and second-quarter financial updates

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

Somaxon second-quarter net loss reduces to $5.7 million

Seattle Genetics, Genentech expand antibody-drug conjugate collaboration

UT Dallas receives grant from NIH to investigate nerve stimulation for tinnitus

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

FDA advisory committee votes in favor of investigational anti-epileptic drug ezogabine

Study examines cosmetic impact of surgical procedure for body dysmorphic disorder

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Syndax raises $6 million to support ENCORE 301 study in breast cancer

Scientists find therapeutic potential of stem cells for acute lung injury

Augmenix announces commercial implantation of SpaceOAR absorbable spacer system for radiation treatment

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News